Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Lynch syndrome
MSI-H
nivolumab
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
17
5
2019
pubmed:
17
5
2019
medline:
30
6
2019
Statut:
ppublish
Résumé
Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab.
Identifiants
pubmed: 31092773
doi: 10.2169/internalmedicine.1673-18
pmc: PMC6548921
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1479-1484Références
Hum Mutat. 2003 Sep;22(3):258
pubmed: 12938096
Chem Rev. 2006 Feb;106(2):302-23
pubmed: 16464007
J Med Genet. 2007 Jun;44(6):353-62
pubmed: 17327285
J Natl Cancer Inst. 2012 Sep 19;104(18):1363-72
pubmed: 22933731
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255